Ipsen starts resupply of Increlex

|About: Ipsen S.A. ADR (IPSEY)|By:, SA News Editor

Ipsen's (IPSEY -1%) U.S. affiliate Ipsen Biopharmaceuticals says one batch of its orphan drug Increlex (mecasermin [rDNA origin] injection) will be available in the U.S. on June 2. Additional lots will be available over the coming months.

Increlex is used to treat children afflicted with a form of growth failure known as severe primary IGF-1 deficiency which can cause permanent short stature.

The supply interruption began almost a year ago due to manufacturing problems at Lonza Biologics, the maker of Increlex's active ingredient.